Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-SARS-CoV-2 immunoglobulin for treatment of COVID-19 (intramuscular, randomized, placebo-controlled)
2020-005410-18Phase 2Terminated
- Sponsor
- SPSK 1 Lublin
- Start
- Nov 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Anti SARS-CoV-2 immunoglobulin arm with Placebo arm (2 arms). Started Nov 2020; status: terminated.
02
Drugs
anti SARS-CoV-2 immunoglobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005410-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005410-18.